Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment

Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment

Background: B-cell maturation antigen (BCMA)-targeted T cell-redirecting immunotherapies, including Chimeric Antigen Receptor (CAR) T-cell therapy and T-cell engagers have demonstrated remarkable success in treating relapsed/refractory (RR) multiple myeloma (MM), a malignancy of plasma cells. Howeve...

Full description

Bibliographic Details
Main Authors: Minchuan Zhang, Han Ping Loh, Shiyi Goh Fang, Yuansheng Yang, Kong-Peng Lam, Shengli Xu
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Antibodies
Subjects:
NK cells
bispecific antibodies
multiple myeloma
functionality
format
NKCE
Online Access:https://www.mdpi.com/2073-4468/13/4/97

Internet

https://www.mdpi.com/2073-4468/13/4/97

Similar Items